Eisai

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

Retrieved on: 
Wednesday, December 13, 2023
Ministry of Health (Kuwait), Ministry, Brain, Risk management, Amyloid-related imaging abnormalities, Disease, Risk, History, Patient, CET, Intraparenchymal hemorrhage, Eisai, MCI, Alzheimer's disease, Marketing, Horseshoe kidney, Co-promotion, Ageing, ARIA, Hypersensitivity, NHI, HIV disease progression rates, Lecanemab, Medical device, Pharmaceutical industry, Residential care, Biogen, Health

LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.

Key Points: 
  • LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.
  • The launch, planned for December 20, will make Japan the second country to have the product on the market, following the U.S.
    "This is a great Christmas present!
  • Alzheimer's disease patients in Japan will now have access to the first disease modifying treatment.
  • This gives hope for the large aging population in Japan with a great need for new treatment options," says Gunilla Osswald, CEO of BioArctic.

POPULAR SCIENCE ANNOUNCES THE BEST INNOVATIONS OF 2023

Retrieved on: 
Wednesday, November 29, 2023
Dark, Alzheimer's disease, Pfizer, European Space Agency, Fake News Awards, RSV, Sony, Coffee, Unistellar, Science, Anker Innovations, Eisai, Juice, FDA, Meta, Health, Volvo, EV9, Vacuum, De'Longhi, Logitech, Malden Mills, Polaris, Kia, Pharmaceutical industry

NEW YORK, Nov. 29, 2023 /PRNewswire/ -- Today, Popular Science proudly announced their annual Best of What's New Award winners .

Key Points: 
  • NEW YORK, Nov. 29, 2023 /PRNewswire/ -- Today, Popular Science proudly announced their annual Best of What's New Award winners .
  • Each year, the editors rigorously assess thousands of products and technologies in search of the most exciting and revolutionary innovations.
  • "Since 1988, Popular Science has proudly celebrated the groundbreaking innovations changing our world.
  • The Best of What's New Awards showcase the year's radical ideas that are improving our everyday lives and our futures," said Annie Colbert, Popular Science Editor-in-Chief.

CancerCare® Announces Appointment of Christine Verini to CEO

Retrieved on: 
Wednesday, November 29, 2023
Woman, Walter Verini, Eisai, Quality of life, Trustee, University, Cancer, HealthyWomen, Retirement, Saint John's University, Corporate communication, Management, Nursing, Science, Pharmacy

NEW YORK, Nov. 29, 2023 /PRNewswire/ -- CancerCare®, the leading national nonprofit organization providing free, professional support services to anyone affected by cancer, announced today the appointment of Christine Verini as its new Chief Executive Officer, effective December 1. This appointment is an integral part of the organization's strategic leadership transition plan following the retirement of Patricia J. Goldsmith. Given her extensive patient-focused expertise and strong commitment to CancerCare's mission, Ms. Verini is ideally positioned to guide the organization into the future.

Key Points: 
  • This appointment is an integral part of the organization's strategic leadership transition plan following the retirement of Patricia J. Goldsmith.
  • Given her extensive patient-focused expertise and strong commitment to CancerCare's mission, Ms. Verini is ideally positioned to guide the organization into the future.
  • Ms. Verini brings over twenty years of oncology expertise, as well as a strategic vision for the organization.
  • Prior to joining CancerCare, Ms. Verini has held several leadership roles in the health care sector.

CMI Inc. and Life Molecular Imaging Announce the Reimbursement of the Amyloid-PET Diagnostic Neuraceq® (florbetaben 18F) in Japan

Retrieved on: 
Wednesday, November 22, 2023
Ministry, Brain, Alzheimer's disease, CMI, Welfare, Patient, LMI, MCI, PMDA, Amyloid, Diagnosis, Trial of the century, PET, Physician, Dementia, Medical imaging, Eisai, Health

TOKYO and BERLIN, Nov. 22, 2023 /PRNewswire/ -- CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the amyloid-PET diagnostic  Neuraceq® (florbetaben 18F injection) has been approved from the Ministry of Health, Labor, and Welfare to be reimbursed by governmental health insurance. With this C2 path approval, Neuraceq®-PET is the first amyloid PET diagnostic tool currently reimbursed in Japan. Neuraceq® is available in Japan from the approved medical device 放射性医薬品自動合成装置Synthera+ (PMDA medical device license no. 30100BZX0016900) and is currently accessible at Keio University Hospital, Tokyo, Koseikai Takeda Hospital, Kyoto and Uozumi Clinic, Kumamoto. CMI Inc. plans to set up Neuraceq® production at further hospital radiopharmacy sites.

Key Points: 
  • With this C2 path approval, Neuraceq®-PET is the first amyloid PET diagnostic tool currently reimbursed in Japan.
  • Neuraceq® is available in Japan from the approved medical device 放射性医薬品自動合成装置Synthera+ (PMDA medical device license no.
  • 30100BZX0016900) and is currently accessible at Keio University Hospital, Tokyo, Koseikai Takeda Hospital, Kyoto and Uozumi Clinic, Kumamoto.
  • With the reimbursement of this diagnostic tool, Japanese physicians can use this state-of-the-art imaging technology to accurately evaluate their patients with cognitive decline.

Lecanemab winner in two categories at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023
Research, Pathology, Clinical trial, Patient, CET, Eisai, Alzheimer's disease, Co-promotion, Scrip, Boxed, HIV disease progression rates, Pharmaceutical industry, Biogen

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
  • The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
  • It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 20, 2023, at 08.30 a.m. CET.

Lecanemab winner in two categories at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023
Research, Pathology, Clinical trial, Patient, CET, Eisai, Alzheimer's disease, Co-promotion, Scrip, Boxed, HIV disease progression rates, Pharmaceutical industry, Biogen

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
  • The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
  • It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 20, 2023, at 08.30 a.m. CET.

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Retrieved on: 
Tuesday, November 7, 2023
AD, Alzheimer's disease, Neurology, Co-promotion, IDN, CET, Patient, EU, Arms industry, Pharmaceutical industry, Biogen, Eisai

BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Key Points: 
  • BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
  • BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 7, 2023, at 09:15 a.m. CET.

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Retrieved on: 
Tuesday, November 7, 2023
AD, Alzheimer's disease, Neurology, Co-promotion, IDN, CET, Patient, EU, Arms industry, Pharmaceutical industry, Biogen, Eisai

BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Key Points: 
  • BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
  • BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 7, 2023, at 09:15 a.m. CET.

Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF)

Retrieved on: 
Monday, October 30, 2023
FDA, AstraZeneca, Health, Therapy, Biotechnology, Eisai, CG, CCD, Growth, LLP, ACCD, Investment, Simpson Thacher & Bartlett, Patient, Pharmaceutical industry, Thakeham, Pfizer

Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) was significantly oversubscribed, exceeding its target of $300 million.

Key Points: 
  • Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) was significantly oversubscribed, exceeding its target of $300 million.
  • Alongside the Abingworth Clinical Co-Development Fund 2 (ACCD 2), a fund of $583 million, Abingworth has raised over $930 million in new funds since 2021 to invest in the development of late-stage clinical programs from pharmaceutical and biotechnology companies in the US, UK, Europe, and Asia-Pacific, and create innovative therapeutics with potential to significantly improve human health.
  • Abingworth pioneered the clinical co-development (CCD) investment strategy in 2009, investing initially via its venture funds and then through its first dedicated fund, Abingworth Clinical Co-Development Fund (ACCD 1), which launched in 2016 raising $109 million.
  • Overall, across all strategies – venture, growth, and clinical co-development – Abingworth has invested in over 185 life sciences companies over the last 50 years.

LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023

Retrieved on: 
Wednesday, October 25, 2023
Lecanemab, Alzheimer's disease, BEST, AD, Biogen, Health care, TIME, Pathology, Co-promotion, HIV disease progression rates, Dementia, Eisai, Disease, AI, Patient, Pharmaceutical industry

TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.

Key Points: 
  • TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.
  • TIME's annual list of THE BEST INVENTIONS features "200 extraordinary innovations changing lives."
  • TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.
  • We will deliver LEQEMBI to the people with early AD who need it and their families, and aim to continue creating impact on global issues surrounding dementia.